Kole R DeGolier
Overview
Explore the profile of Kole R DeGolier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeGolier K, Danis E, DAntonio M, Cimons J, Yarnell M, Kedl R, et al.
Nat Immunol
. 2025 Jan;
26(1):68-81.
PMID: 39747430
Although chimeric antigen receptor (CAR) T cells are effective against B-lineage malignancies, post-CAR relapse is common, and efficacy in other tumors is limited. These challenges may be addressed through rational...
2.
DeGolier K, Danis E, DAntonio M, Cimons J, Yarnell M, Kedl R, et al.
Res Sq
. 2024 Jan;
PMID: 38196657
Chimeric antigen receptor T cells are an effective therapy for B-lineage malignancies. However, many patients relapse and this therapeutic has yet to show strong efficacy in other hematologic or solid...
3.
Gardell J, Matsumoto L, Chinn H, DeGolier K, Kreuser S, Prieskorn B, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33122397
Background: Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors...
4.
Brempelis K, Cowan C, Kreuser S, Labadie K, Prieskorn B, Lieberman N, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33115946
Background: Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors...